Anixa Biosciences Inc
Nasdaq · Healthcare · Pharmaceutical Preparations · San Jose, CA
ANIX chart
What traders are saying about $ANIX
Latest postsAnixa Biosciences Inc news
- Anixa Biosciences Inc (NASDAQ:ANIX) Stock Now Rated "Hold" by Wall Street Brokerages
MarketBeat ·
- Form 4 Anixa Biosciences Inc: Amit Kumar (Director, CEO) For: 30 October
Investing.com Nigeria ·
- Anixa Biosciences CEO Amit Kumar buys $15,850 in company stock
Investing.com ·
- Anixa Biosciences Stock Price Forecast. Should You Buy ANIX?
StockInvest.us ·
- Anixa Biosciences, Inc. (ANIX) Seasonal returns chart - Yahoo Finance
Yahoo Finance Singapore ·
- Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Yahoo Finance ·
- Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Yahoo Finance ·
- Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Yahoo Finance ·
- Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Yahoo Finance ·
- Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Yahoo Finance ·
- Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Yahoo Finance ·
- Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Yahoo Finance ·
Anixa Biosciences Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $210,000 | $210,000 | – |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M |
| Diluted EPS | $-0.34 | $-0.39 | $-0.32 | $0.45 |
| Total assets (year end) | $15.2M | $18.9M | $25.4M | $28.3M |
| Cash and equivalents (year end) | $1.5M | $1.1M | $998,000 | $9.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Anixa Biosciences Inc
- Ticker
- ANIX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Jose, CA
- Incorporated in
- DE
- Fiscal year end
- October 31
- SEC CIK
- 715446
- Former names
- ITUS Corp, COPYTELE INC
Frequently asked questions
What exchange is Anixa Biosciences Inc listed on?
Anixa Biosciences Inc trades on the Nasdaq under the ticker symbol ANIX.
What industry is Anixa Biosciences Inc in?
Anixa Biosciences Inc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Anixa Biosciences Inc headquartered?
Anixa Biosciences Inc's business address on file with the SEC is in San Jose, CA.
When does Anixa Biosciences Inc's fiscal year end?
Anixa Biosciences Inc's fiscal year ends on October 31.
How much revenue did Anixa Biosciences Inc report?
Anixa Biosciences Inc reported $210,000 in revenue for calendar year 2024, according to its SEC filings.